ArticleJournal of orthopaedic surgery and research2026
Integrative multi-omics analysis reveals gut microbiota-derived metabolites and immune regulatory pathways in osteoarthritis pathogenesis.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- TNFRSF10B Implicated in Osteoarthritis Protection via the Alpha-Tocopherol-to-Sulfate Ratio: A Multiomics and Mendelian Randomization Study.International journal of molecular sciences · 2026Article
- Gut-Intervertebral Disc Axis: Gut Microbiome-Driven Immune-Metabolic Imbalance and Intervertebral Disc Degeneration.Journal of cellular physiology · 2026Review
- Gut microbiota-immune crosstalk in osteoarthritis: pathogenic mechanisms and emerging therapeutic opportunities.Frontiers in microbiology · 2026Review
- Psychological stress and gut microbiota regulation of osteoarthritis progression: mechanisms and therapeutic strategies.Frontiers in microbiology · 2026Review
- Gut Microbiota Regulates Brain-Bone Axis to Influence Osteoporosis Pathogenesis and Treatment.Research (Washington, D.C.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoarthritis (OA) is a chronic degenerative joint disease characterized by cartilage degradation, synovial inflammation, and progressive joint dysfunction. Emerging evidence suggests that gut microbiota dysbiosis contributes to OA development through immune modulation and metabolite-mediated pathways.
methodsWe applied a comprehensive multi-omics strategy that integrated differential gene expression analysis, functional enrichment, machine learning (ML), SHapley Additive exPlanations (SHAP), Mendelian randomization (MR), and single-cell transcriptomics to identify key microbial metabolites and molecular targets involved in OA pathogenesis.
resultsWe constructed a Microbiota-Metabolite-Target (M-M-T) network linking 34 gut microbial species, 19 metabolites, and the hub gene Arginase 1 (ARG1), thereby revealing potential regulatory mechanisms involved in immune cell communication. Functional enrichment analyses and cell-cell interaction profiling identified key roles for the Macrophage Migration Inhibitory Factor (MIF) and visfatin signaling pathways in modulating inflammatory responses and tissue metabolic processes. Seven gut microbiota-derived metabolites with favorable drug-like properties and minimal predicted toxicity were further identified, and molecular docking indicated that these metabolites form stable interactions with ARG1.
conclusionsThese findings provide new insights into the gut-joint axis, suggesting that targeting microbial metabolites and immune regulatory pathways may offer potential therapeutic strategies for OA and pave the way for future in vitro and in vivo investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.